The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 569-571

  Daskapan, Alper ^a   De Lange, Wiel C M ^a   Akkerman, Onno W ^a   Kosterink, Jos G W ^a,b   Van Der Werf, Tjip S ^a   Stienstra, Ymkje ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RALTEGRAVIR; RIFAMPICIN; TENOFOVIR; NITROIMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; CASE REPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; DRUG SENSITIVITY; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LUNG TUBERCULOSIS; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PERSONALIZED MEDICINE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MALE; NITROIMIDAZOLES; OXAZOLES;

EID: 84922192256     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00142614     Document Type: Letter

References (11)

1. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014;44:811-815.
2. Vu DH, Koster RA, Wessels AM, et al. Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2013;917-918:1-4.
3. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788.
4. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011;204:1951-1959.
5. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004;48:4473-4475.
6. Conte JE, Golden JA, Kipps JE, et al. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet 2004;43:395-404.
7. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th Edn. WHO/HTM/TB/2009.420. Geneva, WHO, 2010.
8. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449-1453.
9. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
10. Vu DH, Alffenaar JW, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011;17:2931-2939.
11. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-1420.